Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 3Neoplasms 2Breast Neoplasms 2Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Bone Neoplasms 1Bone Diseases 1

Interventions

Gemcitabine 5Nivolumab 3Irinotecan 3Ipilimumab 3Docetaxel 3Cyclophosphamide 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3pegfilgrastim 2Vincristine 2Temozolomide 2Ibandronic Acid 2Doxorubicin 2CTLA-4 Antigen 2spartalizumab 1saracatinib 1samarium Sm-153 lexidronam 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1fludarabine 1anlotinib 1angiotensin I (1-7) 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Topotecan 1Taxes 1Sunitinib 1Samarium 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Neoplasms × saracatinib × Clear all
NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

Phase 2 Completed
139 enrolled 23 charts
BreastGenitourinarySarcoma

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡